Population pharmacokinetic (popPK) model of pembrolizumab (pembro; MK-3475) in patients (pts) treated in KEYNOTE-001 and KEYNOTE-002.
Tara C. Gangadhar(University of Pennsylvania), Adil Daud(University of California, San Francisco), Gregory M. Lubiniecki(Merck & Co., Inc., Rahway, NJ, USA (United States)), Omid Hamid(Cedars-Sinai Medical Center), Marianne van Vugt(Merck & Co., Inc., Rahway, NJ, USA (United States)), Anna Kondic(Merck & Co., Inc., Rahway, NJ, USA (United States)), Amita Patnaik(South Texas Accelerated Research Therapeutics), Matteo S. Carlino(The University of Sydney), Antoni Ribas(University of California, Los Angeles), F. Stephen Hodi(Harvard University), Christian U. Blank(The Netherlands Cancer Institute), Malidi Ahamadi(Merck & Co., Inc., Rahway, NJ, USA (United States)), Caroline Robert(Institut Gustave Roussy), Janice M. Mehnert(NYU Langone Health), Soonmo Peter Kang(Merck & Co., Inc., Rahway, NJ, USA (United States)), Scot Ebbinghaus(Merck & Co., Inc., Rahway, NJ, USA (United States)), Rik de Greef(Merck & Co., Inc., Rahway, NJ, USA (United States)), Tomoko Freshwater(Merck & Co., Inc., Rahway, NJ, USA (United States))
Cited by 6
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k